Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BillionToOneBLLN -0.25%15 Return-on-Tangible-Equity is 6.18% as of Jun. 2026, which is 6% below its 10-year median of 6.55. GuruFocus rates BLLN with a GF Score™ of 15/100. The stock has 4 warning signs investors should review. Among 187 Medical Diagnostics & Research companies, BillionToOne ranks better than 73.26% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. BillionToOne's annualized net income for the quarter that ended in Jun. 2026 was $32.2 Mil. BillionToOne's average shareholder tangible equity for the quarter that ended in Jun. 2026 was $521.2 Mil. Therefore, BillionToOne's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 6.18%.
The historical rank and industry rank for BillionToOne's Return-on-Tangible-Equity or its related term are showing as below:
BLLN'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 6.55 Med: 6.55 Max: 18.27
Current: 18.27
During the past 3 years, BillionToOne's highest Return-on-Tangible-Equity was 18.27%. The lowest was 6.55%. And the median was 6.55%.
BLLN's Return-on-Tangible-Equity is ranked better than 73.26% of 187
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.34
vs BLLN: 18.27
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
BillionToOne Return-on-Tangible-Equity Related Terms
BillionToOne Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for BillionToOne's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLLN vs TWST, SHC, RDNT: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, BillionToOne's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BillionToOne Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BillionToOne's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where BillionToOne's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 6.18% mean?
BillionToOne (BLLN) has a Return-on-Tangible-Equity of 6.18% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on BillionToOne and its competitors. This is near median its historical median of 6.55. Over the past decade, BillionToOne's Return-on-Tangible-Equity has ranged from 6.55 to 18.27. According to the industry distribution chart, BillionToOne ranks #50 out of 187 companies in the Medical Diagnostics & Research industry, placing it in the top 26.7%.
Is BillionToOne's Return-on-Tangible-Equity too high?
BillionToOne's current Return-on-Tangible-Equity of 6.18% is near median its 10-year median of 6.55. Over the past 10 years, this metric has ranged from a low of 6.55 to a high of 18.27. The Medical Diagnostics & Research industry median Return-on-Tangible-Equity is 0.34. BillionToOne's value of 6.18% is 1717.6% above this industry median. Based on the distribution chart, BillionToOne ranks #50 out of 187 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, BillionToOne has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does BillionToOne's Return-on-Tangible-Equity compare to TWST and SHC?
According to the Medical Diagnostics & Research industry distribution chart, BillionToOne ranks #50 out of 187 companies for Return-on-Tangible-Equity. This puts BillionToOne in the upper half of its industry. The industry median Return-on-Tangible-Equity is 0.34. BillionToOne's value of 6.18% is 1717.6% above this benchmark. Historically, BillionToOne's own Return-on-Tangible-Equity has ranged from 6.55 to 18.27 over the past decade. While the company's 10-year median is 6.55 vs. the industry median of 0.34, BillionToOne has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
The median Return-on-Tangible-Equity among Medical Diagnostics & Research companies is 0.34, based on 187 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BillionToOne's current Return-on-Tangible-Equity of 6.18% is 1717.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on BillionToOne and its competitors. For the Medical Diagnostics & Research industry, the median Return-on-Tangible-Equity is 0.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BillionToOne's current Return-on-Tangible-Equity is 6.18%, which is near median its own 10-year median of 6.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BillionToOne stock overvalued right now?
BillionToOne (BLLN) has a current Return-on-Tangible-Equity of 6.18%. The current Return-on-Tangible-Equity is 6.18%, which is near median its 10-year median of 6.55 and 1717.6% above the Medical Diagnostics & Research industry median of 0.34. BillionToOne's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For BillionToOne (BLLN), the current Return-on-Tangible-Equity is 6.18% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
15GF Score
Get the complete analysis for BLLN
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLLN has been successfully added to your 
